Jinju Chen

Y Building, 230 Haike Road
Shanghai, 201210, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Corrigendum to "Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation" [Eur. J. Med. Chem. 223 (2021) 11-05 113645].

Corrigendum to "Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation" [Eur. J. Med. Chem. 223 (2021) 11-05 113645].

Journal: European journal of medicinal chemistry
Published: March 29, 2023

Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor.

Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor.

Journal: European journal of medicinal chemistry
Published: June 23, 2022

HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations.

HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations.

Journal: Molecular cancer therapeutics
Published: October 09, 2021

Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile.

Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile.

Journal: Journal of medicinal chemistry
Published: June 17, 2021

Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.

Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.

Journal: European journal of medicinal chemistry
Published: April 02, 2021

Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance.

Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance.

Journal: European journal of medicinal chemistry
Published: December 17, 2019

Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.

Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.

Journal: Journal of medicinal chemistry
Published: September 21, 2019

A selective chromofluorogenic chemodosimeter for fluoride ions based on distyrylbenzenes derivatives containing dual Si-O groups.

A selective chromofluorogenic chemodosimeter for fluoride ions based on distyrylbenzenes derivatives containing dual Si-O groups.

Journal: Luminescence : the journal of biological and chemical luminescence
Published: July 09, 2015

Anion binding modes in cis-trans-isomers of a binding site-fluorophore-π-extended system.

Anion binding modes in cis-trans-isomers of a binding site-fluorophore-π-extended system.

Journal: Chemical communications (Cambridge, England)
Published: October 16, 2014

Chromogenic and fluorescent 'turn-on' chemodosimeter for fluoride based on a F(-)-triggered cascade reaction.

Chromogenic and fluorescent 'turn-on' chemodosimeter for fluoride based on a F(-)-triggered cascade reaction.

Journal: Luminescence : the journal of biological and chemical luminescence
Published: July 22, 2014

A novel chemodosimeter for fluoride ions based on deprotonation of the C-H group followed by an autoxidative decyanation process.

A novel chemodosimeter for fluoride ions based on deprotonation of the C-H group followed by an autoxidative decyanation process.

Journal: Chemical communications (Cambridge, England)
Published: October 12, 2013
Showing 1-11 of 11

Last Updated: 09/26/2026